## Nateglinide-d<sub>5</sub>

MedChemExpress

| Cat. No.:          | HY-B0422S  |       |          |  |  |
|--------------------|--|-------|----------|--|--|
| CAS No.:           | 1227666-13-8   |       |          |  |  |
| Molecular Formula: | C <sub>19</sub> H <sub>22</sub> D <sub>5</sub> NO <sub>3</sub> |       |          |  |  |
| Molecular Weight:  | 322.45   |       |          |  |  |
| Target:            | Potassium Channel; Dipeptidyl Peptidase                        |       |          |  |  |
| Pathway:           | Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease    |       |          |  |  |
| Storage:           | Powder   | -20°C | 3 years  |  |  |
|                    | In solvent   | -80°C | 6 months |  |  |
|                    |  | -20°C | 1 month  |  |  |

## SOLVENT & SOLUBILITY

|                              | Mass<br>Solvent<br>Concentration | 1 mg      | 5 mg       | 10 mg      |
|------------------------------|----------------------------------|-----------|------------|------------|
| Preparing<br>Stock Solutions | 1 mM                             | 3.1013 mL | 15.5063 mL | 31.0126 ml |
|                              | 5 mM                             | 0.6203 mL | 3.1013 mL  | 6.2025 mL  |
|                              | 10 mM                            | 0.3101 mL | 1.5506 mL  | 3.1013 mL  |

| BIOLOGICAL ACTIVITY       |   |  |  |  |  |  |
|---------------------------|---|--|--|--|--|--|
|                           |   |  |  |  |  |  |
| Description               | Nateglinide-d <sub>5</sub> is a deuterium labeled Nateglinide. Nateglinide, a D-phenylalanine derivative, is an orally active and short-<br>acting insulinotropic agent and a DPP IV inhibitor. Nateglinide inhibits ATP-sensitive K+ channels in pancreatic β-cells.<br>Nateglinide is used for the treatment of type 2 (non-insulin-dependent) diabetes mellitus[1][2]. |  |  |  |  |  |
| IC <sub>50</sub> & Target | DPP-4   |  |  |  |  |  |

## REFERENCES

[1]. Christopher J. Dunn, et al. Nateglinide. OFILE Drugs 2000 Sep: 60 (3): 6.

[2]. Shiling Hu, et al. Interaction of nateglinide with KATP channel in h-cells underlies its unique insulinotropic action. European Journal of Pharmacology. 442 (2002) 163-171.

[3]. Jian Luo, et al. Evaluating insulin secretagogues in a humanized mouse model with functional human islets. Metabolism. 2013 Jan;62(1):90-9.

D

[4]. Duffy NA, et al. Effects of antidiabetic drugs on dipeptidyl peptidase IV activity: nateglinide is an inhibitor of DPP IV and augments the antidiabetic activity of glucagonlike peptide-1. Eur J Pharmacol. 2007 Jul 30;568(1-3):278-86.

## Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA